# Respiratory Symptoms in Palliative Care

Dr. David Murphy

Palliative Medicine SpR Beaumont Hospital

Thanks to:

Dr. Val O' Reilly, Palliative Medicine Consultant, Beaumont Hospital Dr. Elaine Cunningham, Palliative Medicine SpR

#### Introduction

- Breathlessness
- Cough
- Secretions

#### Breathlessness

o Frequently cited as the most disabling symptom in cancer and non-malignant illness

- Exacerbations most likely to trigger
  - Unscheduled attendances & carer distress in both cancer & non-cancer patients
  - Up to 25% ED attendances in UK & US due to uncontrolled breathlessness<sup>2</sup>

<sup>1.</sup> Solano, Gomes et al A comparison of symptom prevalence in far advanced cancer, AIDS, chronic obstructive pulmonary disease, heart and renal disease J Pain Symptom Manage 2014

<sup>2.</sup> Gmoseth R et al Predictors of dyspnoea prevalence – results from the BOLD study Eur Resp J 2014

# Breathlessness – Epidemiology

- $\circ$  Chronic breathlessness > 6-8 weeks, arbitrary cut off <sup>1</sup>
- Highly prevalent in community, increases near death
  - 17% in those > 65 yrs
- Prevalence high across all diagnoses of life limiting illnesses<sup>2,3</sup>
  - Cancer 16-70%, Heart failure 18-88%, COPD 56-98%, MND 81-86%
- Patients with cancer experience less breathlessness than chronic nonmalignant illness - significant in last 3 months
- o 26% in receipt palliative care severe breathlessness in final 3 months life

<sup>1.</sup> Ekstrom M, Abernethy A, Currow DC The management of chronic breathlessness in patients with advanced and terminal illness BMJ 2015

<sup>2.</sup> Moens K, Higginson IJ Are there differences in the prevalence of palliative care related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review J Pain Symptom Manage 2014

<sup>3.</sup> Solano, Gomes et al A comparison of symptom prevalence in far advanced cancer, AIDS, chronic obstructive pulmonary disease, heart and renal disease

#### Breathlessness – the nature of the problem

- o Complex multi-dimensional symptom with a myriad of contributors to breathlessness experience<sup>1</sup>
- o Previous experiences, context, anxiety & panic

<sup>1.</sup> Lovell N, Etkind S et al Control and context are central for people with advanced illness experiencing breathlessness – a systematic review and thematic synthesis J Pain Symptom Manage 2014

#### Breathlessness as a symptom


- Burden of dyspnoea co-exists concurrent fatigue, cough, anxiety & depression
- Confer significant functional limitation
- Devastating effect on quality of life
  - concept of 'total breathlessness'
- Associated with poor prognosis, particularly when breathless at rest

- Clinicians recognise significant impact on patients<sup>1</sup> but
  - Time constraints
  - Inadequate access to resources & training
  - Ill-equipped in assessment & management

<sup>1.</sup> Young, Donahue Farquahar M Using opioids to treat dyspnoea in advanced COPD – attitudes of family physicians and respiratory therapists Can Fam Medicine 2012


#### Devastating effect on quality of life

concept of 'total breathlessness'




<sup>1.</sup> Lovell N, Etkind S et al Control and context are central for people with advanced illness experiencing breathlessness —a systematic review and thematic synthesis J Pain Symptom Manage 2014

## The spiral of dyspnoea disability



 Intimately related to physical & emotional exertion – avoidance, resulting in vicious cycle of deconditioning and further breathlessness on exertion

#### Breathing, Thinking, Functioning Model



#### Impact & Experience of breathlessness

Frightening, disabling & restricting... pervades every part of life<sup>1,2</sup>

Support highly valued – but provided inconsistently & sporadically<sup>1</sup>

Stoical philosophical approach to live with impact of breathlessness<sup>1</sup>

Restrictions imposed affected lives profoundly<sup>1,2</sup>

Feelings of isolation & invisibility<sup>1,2</sup>

Perceived lack of interest or response from clinicians<sup>2</sup>
- retreat from seeking help

<sup>1.</sup> Booth S, Silvester S, Tood C et al, Breathlessness in cancer and chronic obstructive pulmonary disease – using a qualitative approach to describe the experience of patients and carers Palliat Support Care 2003

<sup>2.</sup> Lovell N, Etkind S et al Control and context are central for people with advanced illness experiencing breathlessness —a systematic review and thematic synthesis J Pain Symptom Manage 2014

#### Not just the patients... Informal carers

> BMC Palliat Care. 2020 May 6;19(1):64. doi: 10.1186/s12904-020-00572-7.

Two faces of the same coin: a qualitative study of patients' and carers' coexistence with chronic breathlessness associated with chronic obstructive pulmonary disease (COPD)

Diana H Ferreira <sup>1</sup>, Slavica Kochovska <sup>2</sup>, Aaron Honson <sup>3</sup>, Jane L Phillips <sup>2</sup>, David C Currow <sup>3</sup> <sup>2</sup>

- Growing, substantial body of evidence demonstrate that carers of those with breathlessness may experience profound anxiety, exhaustion and poor sleep
- Heightened when witnessing breathlessness paroxysms
  - powerless to help
- Living with uncertainty, shrinking world
- Exhausted by extra physical work & psychological support required

<sup>1.</sup> Booth S, Silvester S, Tood C et al, Breathlessness in cancer and chronic obstructive pulmonary disease – using a qualitative approach to describe the experience of patients and carers Palliat Support Care 2003

#### **Assessment of Breathlessness**





#### Assessment of Breathlessness

- Subjective experience 'a sensation, not a physiological variable<sup>1'</sup>
- Screen at every assessment
- Gold standard for assessment of breathlessness is patient selfreport


#### Assessment of Breathlessness


'Are you short of breath..?'
VS.

'What activities have you reduced or given up as a result of breathlessness?'

- Objective physiological measures complement assessment <u>but</u> weak association with subjective sensation of breathlessness
  - Presence and severity of breathlessness for an individual cannot be predicated by variables such as oxygen saturations, respiratory rate<sup>1</sup>
  - Lung function tests correlate poorly with breathlessness experience
  - Agreement between doctors and patients on rating of breathlessness was 45%

# Uni-dimensional & functional tools for assessment





#### Figure 6. The Modified Medical Research Council Dyspnea Scale

#### **mMRC Breathlessness Scale**

Grade	Description of Breathlessness
0	I only get breathless with strenuous exercise
1	I get short of breath when hurrying on level ground or walking up a slight hill
2	On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace
3	I stop for breath after walking about 100 yards or after a few minutes on level ground
4	I am too breathless to leave the house or I am breathless when dressing

Chris Stenton. The MRC breathlessness scale. Occup Med (Lond)(2008)58(3): 226-227 doi:10.1093/occmed/kqm162, Table 1. By permission of Oxford University Press on behalf of the Society of Occupational Medicine.

A mMRC score of 1 or more suggests significant symptoms.

mMRC=modified Medical Research Council

74 year old lady with Metastatic Breast Carcinoma Progressive dyspnoea, intermittent wheeze & dry nocturnal cough

Panic, spiralling & impact on daily ADLs, ability to live alone

 Potential differentials for this lady's symptomatic presentation?



#### **Cancer related**

- Pulmonary metastatic disease
- Effusions Pleural or Cardiac
- Superior Vena Caval Obstruction
- Lymphangitis Carcinomatosis



#### **Treatment related**

- Post radiotherapy
- Chemotherapy
  - Cardiac or pulmonary toxicity
- Surgical
- Chest wall resection, phrenic nerve damage

#### **Co-morbid issues**

- Infection
- Concurrent anaemia
- Thrombo-embolism
- Deconditioning as a result of weight loss & in-activity

#### Factors for consideration


Decision making will be influenced by your patient's **preferences**, **performance status & estimated prognosis** 

- Reverse the reversible
  - ✓ Actively seek infection including atypical
  - ✓ Consider therapeutic thoracocentesis, indwelling Pleurex® drain
  - ✓ Diuretic therapy trial if compelling features of de-compensated heart failure
  - ✓ Lymphangitis carcinomatosis/Superior Vena Caval Obstruction
    - high dose steroids e.g. Dexamethasone 8mg od- bd po
    - Stenting, suitability for thoracic radiotherapy

# Approach to management

#### Hierarchy of Management

- 1. Correct the correctable
- 2. Non-Pharmacological
- 3. Pharmacological
  - opiate therapy
  - benzodiazepines
  - oxygen therapy
  - antidepressants ?




#### Non Pharmacological Management

- Cornerstone in management
- Complements & may be superior to use of pharmacological interventions for some patients
- Vital in promoting breathlessness mastery
- Harness and use early in trajectory of advancing illness
  - window of opportunity
  - may be less useful as illness progesses & prognosis shortens

#### Non-Pharmacological Management

#### 1. Breathing re-training


Pursed Lip Breathing,
Timed breathing
Diaphragmatic breathing





#### 2. Positioning – recovery & empowerment


Box 1 Joint British Thoracic Society and Association of Chartered Physiotherapists in Respiratory Care (BTS/ACPRC) guidance on positioning to relieve breathlessness<sup>33</sup> 35



#### Non-Pharmacological Management

# 3. Guided Imagery & Relaxation techniques





#### 4. Education & Self-Management

- Emphasis that experiencing breathless not harmful – dispel fear of provoking breathlessness
- Activity pacing
- Use of mobility aid for ambulation & functional activities

Role of pulmonary rehabilitation

#### Non-Pharmacological Management

BMC Palliat Care. 2010; 9: 22.

Published online 2010 Oct 19. doi: 10.1186/1472-684X-9-22

PMID: 20958972

Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial



PMCID: PMC2974661

- Role of hand held fan
- Under-rated, simple intervention to promote self management
- Cheap, minimal adverse effects
- Mode of action
  - generate air flow across nasal receptors in trigeminal distribution, moderates afferent signal to respiratory centre
  - enhanced self efficacy, particularly with paroxysms

## 1. Pharmacological options - Opiates

- Opiates the largest & most compelling evidence base for alleviation of breathlessness - though poor quality, conflicting.
- Reduce sensation of work of breathing
  - Act centrally
  - Via opiate receptors in pulmonary vasculature to promote vasodilation.
- Most evidence (although limited) relates to morphine
  - Oramorph(IR) 2.5mg po can establish on TDS/QDS dose
  - Low dose sustained release MST(Morphine sulphate Tablet)<sup>1</sup>
  - More than 90% people respond to 20mg OME daily or less1
- Concern about respiratory depression overstated
  - small dose increments & titrate slowly.


#### 2. Pharmacological options - Benzodiazepines

**Cochrane Database of Systematic Reviews** 

# Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults

Cochrane Systematic Review - Intervention | Version published: 20 October 2016 | see what's new

- Evidence for efficacy in relief of breathlessness inconclusive in both malignant and nonmalignant disease<sup>1</sup>
  - little benefit if prescribed in isolation
- Can be helpful in short term relief of panic associated with paroxysms
- Tolerance & exacerbation of delirium an issue





#### 3. Pharmacological Management – Oxygen therapy

**BTS Guidelines** 

# British Thoracic Society guidelines for home oxygen use in adults

- Indicated ONLY if confirmed hypoxia
- Patients with cancer or advanced cardio-respiratory illness with intractable breathlessness should <u>not</u> receive Palliative Oxygen therapy (POT) if they are non-hypoxaemic (SpO2 > 92%)
- Burst oxygen if episodic breathlessness?



#### 4. Pharmacological Management – Corticosteroids

Cochrane Database of Systematic Reviews | Review - Intervention

# Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults

Alison Haywood, Jacqueline Duc, Phillip Good, Sohil Khan, Kirsty Rickett, Petra Vayne-Bossert, Manual Janet R Hardy Authors' declarations of interest

Version published: 20 February 2019 Version history

- Evidence base limited, insufficient
- Cochrane review neither supported nor refuted use!
- Corticosteroids felt to be helpful for alleviation of dyspnoea in cancer if
  - √ Central airway obstruction
  - ✓ Lymphangitis carcinomatosis
  - √ Superior vena caval obstruction
- Limited role as maintenance therapy in idiopathic pulmonary fibrosis, interstitial disease
- Adverse effects

## Cough

- Cough is a forced expulsive manoeuvre usually against a closed glottis, which is associated with a characteristic sound.
- It usually has a protective function in maintaining patency and cleanliness of the airways, but may be due to a number of underlying conditions.
- Chronic cough: >8 weeks
- Cough occurs in 50-80% patients with cancer

#### Causes

- COPD
- Infection
- PE
- Cancer e.g. endobronchial tumour, treatment side effect
- Pleural/pericardial effusion
- Congestive cardiac failure
- Aspiration
- Drugs e.g. ACE inhibitors

- Interstitial lung disease
- Postnasal drip
- GORD
- Sinusitis
- Bulbar muscle weakness e.g. MND
- SVCO
- Recurrent laryngeal nerve palsy
- Tracheal compression

#### Assessment

- Explore:
  - understanding of the reasons for cough
  - fears (including fear of choking)
  - o impact on:
    - functional abilities (including continence)
    - quality of life
    - families and carers.
- Clarify:
  - o pattern, character and duration
  - o precipitating/alleviating factors
  - o associated symptoms
  - o occupational history.

- Look for any potentially reversible causes of cough, such as:
  - o infection
  - pleural or pericardial effusion
  - o pulmonary embolism
  - o gastro-oesophageal reflux
  - o bronchospasm.

#### General Management

- Consider treating any potentially reversible causes.
- Optimise current therapy (non-drug management and medication); in particular, ensure adequate analgesia as pain may inhibit effective coughing.
- Acknowledge fear and anxieties, and provide supportive care.
- Consider referral to physiotherapy services if difficulty in expectorating retained secretions.
- Agree a self-management plan which could include:
  - o cough diary
  - smoking cessation advice
  - o improved ventilation such as opening a window, putting on a fan
  - o coping strategies such as:
    - positioning and posture
    - relaxation
    - controlled breathing technique and effective coughing techniques, for example huffing.

## Specific Management - Dry Cough

- COPD (non infective) steroids, inhalers/nebulisers
- PE consider appropriateness of anticoagulation
- Pleural/pericardial effusion drainage
- SVCO steroids
- Tracheal compression radiotherapy, steroids, stenting

#### General Management - Dry Cough

- Cough suppression with opioids:
  - Codeine linctus (not usually if on other opioid)
  - Morphine
    - opioid naive 2mg immediate release orally, 4 to 6 hourly if required.
    - already on morphine continue and use the existing immediate-release breakthrough analgesic dose (oral if able or subcutaneous equivalent) for the relief of cough.
  - Methadone
  - Trial second line GABA agonists e.g. gabapentin/pregabalin, benzodiazepines

# Specific management - Productive Cough

- Infection antibiotics
- COPD (infective exacerbation) antibiotics, steroids, inhalers/nebulisers
- GORD PPI, prokinetic
- Congestive cardiac failure Medical management, diuretics
- Aspiration SALT, altered diet
- Weak productive cough/excessive saliva e.g. MND consider antisecretory
- Sinusitis/postnasal drip nasal spray/decongestant

# General Management - Productive Cough

- Mucolytics to reduce sputum viscosity, for example carbocisteine (Exputex) as required.
- Nebulised sodium chloride 0.9% to help loosen secretions.
- When a patient with a moist cough reaches end of life, cough suppression/drying of secretions may be necessary.

#### Oropharyngeal Secretions

- 'Death rattle', 'noisy', 'rattling', 'harsh', 'gurgling'
- Very common symptom at end of life. 23-92% deaths<sup>1</sup>.
- Sign that death is close
- Emotional response in professionals and carers

<sup>1.</sup> Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD005177. doi: 10.1002/14651858.CD005177.pub2.

#### Causes

- Increased production of airway secretions or inefficient elimination of the mucus or both.
- Fluid collecting in the upper airway from one or more sources:
  - Saliva
  - Bronchial mucosa- infection/ inflammation
  - Pulmonary oedema
  - Gastric reflux

# Who gets them?

- More commonly patients with :
  - lung cancer,
  - chest infections,
  - brain tumours
  - serious head injuries,
  - neuromuscular disorders, especially if associated with dysphagia,
  - cardiac arrest

## Nonpharmacological Management

Counsel and educate families


- Positioning, i.e. head raised or lateral position may help
- Gentle upper airway suction can be considering on a case by case basis if unconscious
- Reduce risk by avoiding fluid overload; review any assisted hydration or nutrition (intravenous or subcutaneous fluids, feeding) if symptoms develop

## Pharmacological

#### Saliva

- Antimuscarinic/anticholinergic i.e. hyoscine butylbromide (buscopan), glycopyrronium
- Early introduction prophylaxis more effective than treatment
- Buscopan 20mg 4hrl PRN or via CSCI (Max 120mg/24hrs)
- Glycopyrronium 400mcg 4hrly PRN or CSCI (Max 2400/3600mcg/24hrs)

#### Antimuscarinics- side effect profile



# Pharmacological

- Bronchial mucosa
  - Unlikely to be appropriate to rx antibiotic if patient dying
- Pulmonary oedema
  - SC furosemide 20-40 mg prn SC/IM/IV
  - Furosemide via CSCI
- Gastric reflux
  - Consider prokinetic/ PPI

#### Conclusion

- Respiratory symptoms are common in our population.
- Complex, difficult to manage.
- · Limited evidence for pharmacological management.
- Distressing for patients, carers, medical professionals.
- Understanding, education is key!